prostate cancer index | prostate cancer | prostatectomy | radiation | hormone | cryosurgery | hifu | wait & see | alternative treatment | diet | articles | contact |

Archive for February, 2010

Nitroglycerin may be able to delay the progression of prostate cancer

Friday, February 5th, 2010 Posted in prostate cancer | No Comments »

According to a group of researchers at Queen’s University in Kingston, Ontario, a very low dose of nitroglycerin may be able to delay the progression of prostate cancer in men with a rising PSA after standard first-line treatment with radiotherapy ...

Effect of androgen deprivation therapy on body composition in men with prostate cancer

Thursday, February 4th, 2010 Posted in prostate cancer | No Comments »

Use of androgen deprivation therapy is associated with changes in body composition including increased fat and decreased lean mass. Limited information exists regarding the rate and extent of these changes. A recent study at Queen's University Belfast, Belfast, Northern Ireland, UK, ...

Prostate cancer diagnosis may affect man’s mind

Wednesday, February 3rd, 2010 Posted in prostate cancer diagnosis | No Comments »

According to a new study published online February 2 in the Journal of the National Cancer Institute, being diagnosed with prostate cancer may increase a man's risk of suicide or cardiovascular death, especially right after diagnosis. According to the study, the ...

Daily fat intake and risk for prostate cancer

Tuesday, February 2nd, 2010 Posted in prostate cancer risks | No Comments »

A research team at University of Nottingham Medical School, UK, has published data from a population-based, case-control study with 512 patients under 60 years of age and 838 controls, conducted in the United Kingdom between 1999 and 2004. Collected data suggest ...

Prostate Cancer Detection: Estimating The Screening Benefit

Monday, February 1st, 2010 Posted in prostate cancer diagnosis | No Comments »

The European Randomized Study of Screening for Prostate Cancer (ERSPC) has demonstrated that screening has the potential for reducing mortality from prostate cancer (PC). In contrast, The Prostate, Lung, Colorectal and Ovarian (PLCO) trial showed no difference in PC mortality after ...